 The U.S.-listed shares of of Immuron Ltd. skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center NMRC has requested a pre-investigational new drug IND meeting with the Food and Drug Administration regarding the treatment being developed for severe campylobactcampylobacteriosis and ETEC infections E-Coli. The stock was trading at 20.65, or 890.4 above Mondays closing price of 2.10. Trading volume blasted off to 65.5 million shares, compared with the full-day average of about 5,900 shares and nearly 15 times the 4.4 million shares outstanding. The Australian Importation permit required to ship the vaccines from the NMRC was approved by Biosecurity Australia and the NMRC vaccines were shipped to our contract research partner to commence the project, said Immuron Chief Executive Jerry Kanellos. The plan is to have the product completed by the end of this year and have it ready for clinical evaluation next year. The stock was down 42.1 year to date as of Mondays close, before Tuesdays rally, while the iShares Nasdaq Biotechnology ETF had gained 10.4 over the same time and the SP; 500 was up less than 0.1. 